Oltipraz
Alternative Names: RP 35972Latest Information Update: 24 Oct 2021
At a glance
- Originator sanofi-aventis
- Developer Sanofi; sanofi-aventis
- Class Chemoprotectants; Organic sulfur compounds; Pyrazines; Small molecules
- Mechanism of Action Glutathione transferase inhibitors; Glutathione transferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV-1 infections; Lung cancer; Parasitic infections
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 07 Jul 2003 Data presented at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO-2003)have been added to the adverse events section
- 09 Apr 2002 A preclinical study has been added to the Cancer pharmacodynamics section